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angiogenic factor, is thought to play a decisive role in remodelling the tumour
microenvironment.
The purpose of this study is to analyze, in an in vivo setting, the transcriptional
response of the tumour stroma in reaction to angiogenic stimuli provided by
the cancer cells.
Materials and Methods: Stroma was microdissected (PALM Microlaser
System) from human ovarian carcinoma xenografts 1A9-VS1 (high VEGF,
N = 5) and 1A9-VAS3 (low VEGF, N = 5), and processed for RNA isolation.
Labeled cRNA was hybridized to GeneChip® Mouse Genome 430 2.0 Arrays
(Affymetrix). Transcriptional differences of the stroma were evaluated by two
approaches: a one-way, modiﬁed and error-weighted Analysis of Variance
(ANOVA) with a P-value cut-off of 0.01 (Resolver SE System, Rosetta
Biosoftware), and the GC_RMA stochastic algorithm (GeneSpring, Agilent).
Validation of microarray data has been performed using Real Time RT-PCR
and immunoﬂuorescence.
Results: VEGF produced by the cancer cells induced the up-regulation
of 294 and down-regulation of 162 genes in the tumour stroma. Among
them, neuropilin-1, endoglin, CXCL2, and collagen IV were conﬁrmed to
be up-regulated, and this was seen not only in the same tumours used
for microarray analysis but also in different biological samples. It has been
described that neuropilin-1 is expressed by endothelial cells and is associated
to VEGF signaling, endoglin and CXCL2 are expressed by endothelial cells and
macrophages, respectively, and collagen IV is associated to the extracellular
matrix. Altogether, these data demonstrate that the VEGF released from
tumour cells alters the tumour microenvironment.
Conclusions: The gene expression differences found from microarray analysis
are robust thus providing the conﬁdence necessary for using the 1A9-
VS1 and 1A9-VAS3 model to investigate the proteins altered in the tumour
microenvironment. Studies are underway in order to study genes/proteins
whose function and characteristics are not well known.
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Background: Tropomyosin-related kinase receptor C (TrkC) is a neurotrophin
receptor with tyrosine kinase activity that could behave as an oncogene.
However, it has several characteristics of a tumour suppressor: its expression
in tumours has often been associated with good prognosis; and it was recently
demonstrated to be a dependence receptor, transducing survival signals in the
presence of ligand and inducing apoptosis in the absence of ligand.
Material and Methods: We have screened human neuroblastomas (NB)
tumours and measured NT-3 expression by RT-Q-PCR and immunohistochem-
istry. We have used NB cell lines in vitro and in an avian and murin model
for tumour progression and investigated the proapoptotic effect of an antibody
targetting NT-3/TrkC binding.
Results: Here we show that the TrkC ligand neurotrophin-3 (NT-3) is
upregulated in a large fraction of aggressive human NBs and that it blocks
TrkC-induced apoptosis of human NB cell lines, consistent with the idea that
TrkC is a dependence receptor. Functionally, both siRNA knockdown of NT-3
expression and incubation with a TrkC-speciﬁc blocking antibody triggered
apoptosis in human NB cell lines. Importantly, disruption of the NT-3 autocrine
loop in malignant human neuroblasts triggered in vitro NB cell death and
inhibited tumour growth and metastasis in both a chick and a mouse xenograft
model.
Conclusions: Thus, our data suggest that NT-3/TrkC disruption is a putative
alternative targeted therapeutic strategy for the treatment of NB.
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Background: Lung cancer is the commonest cause of cancer-related mortality
among both men and women, mostly due to the rapid development of drug
resistance and early metastasis. In this study, we sought to evaluate the
potential involvement of Src family kinases (SFK) in lung cancer biology and
assess the possible beneﬁts of their inhibition as a therapeutic approach for
this disease.
Material and Methods: The following cell lines were used: A549, EKVX,
HOP62, HOP92, H226, H23, H322M, H460, H522, HCC78, HCC95 NSCLC
and U2OS osteosarcoma. Proliferation was assessed using crystal violet
staining and Western Blotting for phospho-Retinoblastoma and p27. DNA
synthesis was quantiﬁed by EdU proliferation assay. Induction of apoptosis
was measured using caspase activity assay, FACS analysis (sub-G1 peak)
and Western Blotting for activated caspases 3, 7 and 9, and PARP
cleavage. Autophagy was monitored by ﬂuorescent microscopy using LC3-
GFP-expressiong cells and by Western Blotting for LC3.
Results: Here, we demonstrate that various Src family members, including
Lyn and Lck, which were believed to be expressed solely in hematopoietic
cells and neural tissues, are overexpressed and activated in vitro in a panel
of SCLC and NSCLC cell lines and in vivo in lung cancer tissue microarrays,
compared to normal lung tissue. Dasatinib (BMS-354825), a novel Src/Abl
inhibitor, effectively blocks SFK activation at nanomolar concentrations which in
turn result in signiﬁcant decrease in cell numbers in the majority of lung cancer
cell lines. However, we failed to detect differences in cell cycle progression
upon dasatinib treatment. Also, we could only detect moderate induction
of apoptosis. In contrast, we demonstrate that dasatinib as well as PP2,
another SFK inhibitor, are strongly inducing autophagy. Last but not least,
we show that combined treatment with dasatinib and etoposide or cisplatin,
chemotherapeutic agents commonly used in lung cancer treatment has an
additive effect.
Conclusions: Overall, our results suggest that inhibition of Src family kinases
alone or in combination with chemotherapeutic treatment, may be a beneﬁcial
therapeutic strategy in the management of lung cancer patients.
374 New tools to evaluate genetic targets and therapeutic strategies
against cancer: in vivo imaging and inducible systems to modify
gene function
O. Buiakova1, Y. Xu1, J. Seibler2, H. Kissel3, E. Roschmann3, E. Michalak4,
K. Nacerddine5, M. van Lohuizen5, J. Jonkers4, D. Grass1. 1Taconic
Cranbury, Scientiﬁc Operations, Cranbury, USA, 2TaconicArtemis, Technology
Development, Ko¨ln, Germany, 3TaconicArtemis, Business Development, Ko¨ln,
Germany, 4The Netherlands Cancer Institute, Division of Molecular Biology,
Amsterdam, The Netherlands, 5The Netherlands Cancer Institute, Division of
Molecular Genetics, Amsterdam, The Netherlands
Background: More predictive small animal models for compound and
genetic target assessment are needed. We have used in vivo and ex
vivo bioluminescent imaging technology to create oncology models to
evaluate compound efﬁcacy in mouse models of orthotopic tumour growth
and spontaneous metastases. Orthotopic tumour models are more relevant
with respect to host-tumour interactions, characteristic disease progression,
metastatic potential and response to therapy than the currently used
(subcutaneous) models for preclinical drug selection.
Materials and Methods: PC3-M-luc human prostate adenocarcinoma cells
that were genetically modiﬁed to express ﬁreﬂy luciferase were inoculated
orthotopically. In vivo bioluminescent imaging (BLI) was performed using an
In Vivo Imaging System (IVIS®) on day 7 post tumour implantation. Taxotere®
was then given at a dose of 20mg/kg by i.v. injection on day 8. Subsequent
tumour growth was monitored by BLI.
Results: Using this BLI-based model system, metastases were detected as
early as 21 days post tumour implantation. After only 5 weeks, a majority of
the mice (~75%) exhibited distant metastases in vivo, which were observed
by shielding the photons emitted from the primary tumour. At the end of
the study, ex vivo tissue BLI was performed on the lungs, diaphragms, liver,
draining lymph nodes, brains and femurs of all of the animals. We were able
to detect metastases in all of the animals imaged ex vivo (even those in which
the tumours were too small to detect in vivo) in at least 2 of the evaluated
tissues. Taxotere® effectively inhibited both the primary tumour growth and
the development of metastases. A similar orthotopic/metastatic brain (U87-
MG-luc2) model is in development.
Conclusions: Our platform is highly sensitive and facilitates the development
of orthotopic and metastatic xenograft tumour models, which allow for the
performance of quantitative and high throughput in vivo assessments of
potential anti-neoplastic and/or anti-metastatic therapies. In addition, we are
developing new oncology animal models that will combine inducible/reversible
RNAi gene knockdown and KinaseSwitch technologies with the imaging
technology to assess compound efﬁcacy as well as to evaluate genetic targets
in vivo. Preliminary data will be presented on two mouse models developed
for target validation in breast cancer using inducible shRNA technology and
on KinaseSwitch models which allow investigators to study the biological role
of a speciﬁc kinase and possible side effects that result from its inhibition.
